Empiric Oral Antibiotics for Cellulitis
For non-purulent cellulitis in adults without β-lactam allergy, use cephalexin 500 mg four times daily or dicloxacillin 500 mg four times daily for 5 days, targeting β-hemolytic streptococci. 1, 2, 1
Treatment Algorithm Based on Clinical Presentation
Non-Purulent Cellulitis (No drainage, no abscess)
First-line therapy:
- Cephalexin 500 mg PO four times daily 3
- Dicloxacillin 500 mg PO four times daily 3
- Penicillin VK (alternative)
These β-lactams target β-hemolytic streptococci, which cause the vast majority of non-purulent cellulitis cases 1, 2, 1. The IDSA guidelines explicitly state that empirical therapy for β-hemolytic streptococci is recommended for this presentation, while noting that "the role of CA-MRSA is unknown" 1, 2, 1.
Duration: 5 days is sufficient, extending only if no clinical improvement 1, 2, 4
When to Add MRSA Coverage
Add MRSA-active antibiotics if ANY of these risk factors are present:
- Penetrating trauma
- Evidence of MRSA infection elsewhere or known nasal colonization
- Injection drug use
- Purulent drainage (even without drainable abscess)
- Systemic toxicity/SIRS
- Failure to respond to β-lactam therapy after 48-72 hours 1, 2, 1, 4
MRSA-active oral options when needed:
For dual coverage (streptococci + MRSA):
- Clindamycin 300-450 mg PO three times daily (covers both) 1, 2, 1
- TMP-SMX 1-2 double-strength tablets twice daily PLUS amoxicillin 500 mg three times daily 1, 2, 1
- Doxycycline 100 mg twice daily PLUS amoxicillin 500 mg three times daily 1, 2, 1
- Linezolid 600 mg twice daily (covers both, but expensive) 1, 2, 1
Critical Clinical Nuances
Important caveats about MRSA coverage: The evidence strongly suggests that empirical MRSA coverage is unnecessary for typical non-purulent cellulitis, even in areas with high community MRSA prevalence 5, 6, 7. Multiple studies demonstrate that β-lactam monotherapy (penicillin/cephalosporins) achieves cure rates comparable to broader-spectrum regimens 6, 7. This is because streptococci—not MRSA—are responsible for the vast majority of non-purulent cellulitis cases 5, 8, 7.
Clindamycin considerations: While clindamycin provides convenient dual coverage, be aware of potential cross-resistance with erythromycin-resistant strains and inducible resistance in MRSA 1, 3, 1. Additionally, Clostridioides difficile infection may occur more frequently with clindamycin compared to other oral agents 1.
TMP-SMX limitations: TMP-SMX lacks reliable activity against β-hemolytic streptococci, which is why it must be combined with a β-lactam when used for non-purulent cellulitis 1. It should not be used as monotherapy unless the infection is clearly purulent (suggesting staphylococcal rather than streptococcal etiology).
Common Pitfalls to Avoid
Over-treating with MRSA coverage: The single most common error is reflexively covering MRSA in all cellulitis cases. Reserve MRSA-active agents for the specific risk factors listed above 4, 5, 7.
Diagnosing bilateral cellulitis: Bilateral lower extremity "cellulitis" is rarely infectious—consider venous stasis dermatitis, contact dermatitis, or dependent edema instead 9, 5.
Excessive treatment duration: Five days is adequate for uncomplicated cases that show clinical improvement 1, 2, 4. Extending beyond this without clear indication promotes resistance.
Using rifampin: Never use rifampin as monotherapy or adjunctive therapy for cellulitis—it is not recommended 1, 2, 1.